SynthesisPloS one2026
The role of obesity and Type 2 diabetes in lung health: A systematic review (2024).
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- It's more than mechanics: the case for metabolic end-points in airways disease.The European respiratory journal · 2026Review
- The Relationship Between Physical Activity Level, Respiratory Muscle Strength, and Cough Strength in Individuals with Type 2 Diabetes Mellitus: An Observational Cross-Sectional Study.Journal of clinical medicine · 2026Article
- The Inflammation-Metabolism Axis in Preserved Ratio Impaired Spirometry: Pathogenic Mechanisms and Translational Implications.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes is associated with mild airways restriction, yet obstructive lung conditions are prevalent in people with diabetes. Obesity is a confounding factor and has been reported to be both protective and to enhance risk of lung disease independent of hyperglycaemia. The aim of this systematic review was to evaluate how Type 2 diabetes and obesity affect lung function measurements in people with and without chronic obstructive pulmonary disease (COPD) and asthma.
methodsOvid MEDLINE and Embase databases were methodically searched for studies published between 2011-2024. Ninety-three studies were included, with 35,891 participants. Included studies had data on Type 2 diabetes and/or obesity and forced expiratory volume in one second (FEV1) and/or forced vital capacity (FVC). All studies were assessed for quality (Newcastle-Ottawa scale) or risk of bias (Cochrane methodology). Data was extracted as combined means and standard deviation, and significance tested by Kruskal-Wallis. Multiple linear regression was conducted to account for the impact of age, BMI, Type 2 diabetes and geographical region.
resultsThose with Type 2 diabetes without a lung disease had mild airway restriction. However, outcomes for those with asthma and COPD in the presence of Type 2 diabetes were largely comparable to those who had either condition in the absence of Type 2 diabetes. A Type 2 diabetes diagnosis and being in the geographical region of Asia were significantly associated with decreased FEV1 and FVC, but obesity was not. The study is limited by the large number of cross-sectional studies using single time points from which conclusions on causality cannot be drawn.
conclusionType 2 diabetes is independently associated with airways restriction suggesting that monitoring of lung function following a diabetes diagnosis may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.